MedPath

FDA Approves Subcutaneous Tecentriq Hybreza for Multiple Cancer Types

  • The FDA has approved Tecentriq Hybreza, a subcutaneous formulation of atezolizumab, for various cancer indications, offering a new administration route.
  • Approval was based on the IMscin001 trial, which demonstrated comparable atezolizumab exposure between subcutaneous and intravenous administrations.
  • Tecentriq Hybreza combines atezolizumab with hyaluronidase to enhance subcutaneous tissue permeability, facilitating drug delivery.
  • The new formulation provides a faster, approximately 7-minute subcutaneous injection option compared to intravenous infusions.
The U.S. Food and Drug Administration (FDA) has approved Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) for subcutaneous (SC) injection, providing a new administration option for patients across several cancer types. This approval covers all indications previously approved for intravenous atezolizumab, including non-small cell lung cancer (NSCLC), small cell lung cancer, hepatocellular carcinoma, melanoma, and alveolar soft part sarcoma.
Tecentriq Hybreza combines atezolizumab, a PD-L1 blocking antibody, with hyaluronidase, an endoglycosidase that increases the permeability of subcutaneous tissue. This combination allows for subcutaneous administration, offering a potentially faster and more convenient alternative to intravenous infusions.

IMscin001 Trial Results

The approval was primarily based on data from the IMscin001 trial (NCT03735121), an open-label, randomized study involving adults with locally advanced or metastatic NSCLC who had not previously received immunotherapy and had experienced disease progression following platinum-based chemotherapy. Patients were randomized to receive either Tecentriq Hybreza SC (n=247) or intravenous atezolizumab (n=124) every three weeks until disease progression or unacceptable toxicity. The primary endpoint of the trial was atezolizumab exposure.
Results from the IMscin001 trial demonstrated comparable atezolizumab exposure between the Tecentriq Hybreza and intravenous atezolizumab groups. The confirmed overall response rate (ORR) was 9% in the Tecentriq Hybreza arm and 8% in the intravenous atezolizumab arm, indicating similar efficacy between the two administration routes. Furthermore, no significant differences were observed in progression-free survival (PFS) or overall survival (OS) between the groups.
The most common adverse reactions reported with Tecentriq Hybreza were fatigue, musculoskeletal pain, cough, dyspnea, and decreased appetite. These adverse reactions are consistent with those observed with intravenous atezolizumab.

Dosage and Administration

Tecentriq Hybreza is supplied in a single-dose vial containing 1875 mg of atezolizumab and 30,000 units of hyaluronidase per 15 mL. It is administered subcutaneously into the thigh over approximately 7 minutes, offering a significantly shorter administration time compared to intravenous infusions.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

FDA Approves Novel Therapies for Synovial Sarcoma, Cutaneous T-Cell Lymphoma, and Subcutaneous Atezolizumab

The FDA granted accelerated approval to Tecelra (afamitresgene autoleucel), a T-cell receptor therapy, for inoperable or metastatic synovial sarcoma, marking the first TCR therapy for solid tumors.

FDA Approves Subcutaneous Atezolizumab (Tecentriq Hybreza) for Multiple Cancers

The FDA has approved atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza) as a subcutaneous injection for all adult indications where intravenous atezolizumab is approved.

FDA Approves Lebrikizumab (Ebglyss) for Moderate-to-Severe Atopic Dermatitis

The FDA has approved lebrikizumab (Ebglyss) for treating moderate-to-severe atopic dermatitis in adults and children 12 years and older who weigh at least 88 pounds.

FDA Approves Roche's Tecentriq Hybreza, a Subcutaneous PD-L1 Inhibitor, for Multiple Cancers

The FDA has approved Roche's Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs), a subcutaneous formulation, for multiple cancer types previously approved for the IV form.

FDA Approves Roche's Ocrevus Zunovo for Multiple Sclerosis with Halozyme's Enhanze Technology

The FDA has approved Roche's Ocrevus Zunovo, a subcutaneous formulation for relapsing and primary progressive multiple sclerosis, utilizing Halozyme's Enhanze drug delivery technology.

FDA Approves Roche's Tecentriq Hybreza, a Subcutaneous Anti-PD-(L)1 Cancer Immunotherapy

The FDA has approved Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) as the first subcutaneous PD-(L)1 inhibitor for cancer immunotherapy.

FDA Approves Subcutaneous Ocrelizumab (Ocrevus Zunovo) for Multiple Sclerosis

The FDA has approved subcutaneous ocrelizumab (Ocrevus Zunovo) for relapsing and primary progressive multiple sclerosis (MS).

FDA Approves Roche's Injectable Ocrevus for Multiple Sclerosis

The FDA has approved Roche's subcutaneous injectable version of Ocrevus for treating multiple sclerosis, offering a quicker 7-minute administration time.

FDA Approves Genentech's Tecentriq Hybreza, First Subcutaneous Anti-PD-(L)1 Immunotherapy

The FDA has approved Tecentriq Hybreza, a subcutaneous formulation of atezolizumab, marking the first subcutaneous anti-PD-(L)1 cancer immunotherapy in the U.S.

FDA Approves Subcutaneous Atezolizumab (Tecentriq Hybreza) for Multiple Cancer Types

The FDA has approved a subcutaneous formulation of atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza) for all indications of intravenous atezolizumab.

Reference News

[1]
FDA Approves Tecentriq Hybreza - Cancer Therapy Advisor
cancertherapyadvisor.com · Sep 16, 2024

FDA approves Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) for subcutaneous injection, covering same indicatio...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy